Vivalis Achieves Milestone With Glaxosmithkline in the Development of Human Flu Vaccines Based on Eb66

VIVALIS announced today the achievement of a milestone in its collaboration with GlaxoSmithKline Biologicals to develop new influenza vaccines based on VIVALIS' innovative EB66® cell line technology

NANTES, FRANCE | April 7th, 2010 | VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, announced today the achievement of a milestone in its collaboration with GlaxoSmithKline Biologicals (LSE:GSK - News) to develop new influenza vaccines based on VIVALIS' innovative EB66® cell line technology.

This milestone recognizes the completion of the characterization program of the EB66® cell line according to the current regulatory requirements.

The worldwide collaboration and license agreement is devoted to developing a new way of producing both seasonal and pandemic human influenza vaccines. The EB66® stem cell line technology developed by VIVALIS has the potential to provide greater control and efficiency as compared with the traditional method which uses embryonic chicken eggs.

"We are very pleased with the quality of our collaboration with GSK Biologicals in the area of cell-based influenza vaccine development and with the continued progress of this project. The achievement of this important milestone is the recognition by our partner of the completion of the work done by both our teams to characterize the EB66® cell line. This work did represent a major investment for VIVALIS over the last three years and is a significant step for the development of the EB66® cell line technology not only in the Influenza vaccine field but for all applications", said Franck Grimaud, CEO, and Majid Mehtali, CSO, co- managers of VIVALIS.

SOURCE: VIVALIS

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top